Matrix Analytics' Clinical SaaS Platform LungDirect Set to Revolutionize Incidentaloma and Lung Cancer Screening

DENVER, Sept. 11, 2017 /PRNewswire/ -- Matrix Analytics, a pioneer in cloud based Lung Cancer Screening and Pulmonary Incidentaloma management, announced today it will clinically validate its deep learning and predictive analytics tools for pulmonary nodules. Matrix Analytics, creator of LungDirect, has already developed first in class technology for the management of pulmonary nodules. This technology, leveraged with cloud computing and deep learning, will begin clinical validation later this month. The new tool applies an automated cancer classifier identified in conventional chest CT images to LungDirect's advanced learning algorithms.

"Matrix Analytics is committed to accelerating the transformation of data-driven medicine through advanced cloud medical imaging analytics applications," said Dr. Akrum Alzubaidi, founder of Matrix Analytics. "LungDirect's new tool demonstrates the power of combining deep learning with cloud super computation to aid physicians in understanding pulmonary nodule malignancy risks. Our new technology will accurately automate processes typically done on cumbersome physician workstations and will eliminate the need for antiquated CAD systems."

Unlike computer aided detection (CAD), LungDirect's deep learning tool creates a cancer classifier to guide the algorithm towards a detailed outcome. Deep learning tools have already achieved remarkable diagnostic results and LungDirect will be the first screening and incidentaloma software to incorporate this exciting new technology. Matrix Analytics is partnering with top academic centers to combine imaging techniques, machine learning, and deep EHR integrations to develop big data pipelines that will train LungDirect's platform to achieve superior performance.

About Matrix Analytics: Matrix Analytics is a collection of clinical and business experts aligned in the belief that conquering illness and disease requires data, creativity, and an unrelenting focus on Always Learning. First in our sights: Lung Cancer. Despite recent clinical advancements and available technology, an integrated solution to drive the consistent and efficient detection, diagnosis, and treatment of pulmonary nodules and lung cancer does not exist. LungDirect is the first line of defense by registering pulmonary incidentaloma and screening patients in a dashboard to optimize their follow-up care.